ESR1 and breast cancer: Despite the obvious benefits of TAM in patients at all stages of ERα-positive breast cancer, several studies have reported that the tumors in almost all patients with metastatic disease and in 40% of patients receiving TAM as adjuvant therapy eventually relapse, with a deadly outcome.